2025年7月2日，NMPA公布了创新医疗器械特别审查申请审查结果公示（2025年第6号），宣布来自 深圳大 医伽玛刀科技有限公司 的 头部伽玛射线立体定向放射外科治疗系统 进入创新通道。 在技术层面，CybeRay 采用多束 钴-60 γ射线 ，通过几何聚焦实现高剂量精准照射，靶点定位精度达到 亚毫米 级（<0.5mm） 。系统搭载锥形束 CT（CBCT）或其他实时影像技术，能够在治疗过程中动态校正靶区位置， 显著减少因患者微小运动带来的治疗偏差。此外，其治疗规划软件集成了 AI 优化算法，可在短时间内制定个 体化剂量分布，提升治疗效率。 临床数据显示，CybeRay 的单次治疗时间通常在 30-60 分钟之间，治疗过程无创、无痛，患者无需开颅或住院 长时间观察，术后并发症发生率极低（<0.5%）。2023年，大连大学附属中山医院等国内多家医院已投入 CybeRay 使用，报道显示，患者五年生存率相比传统放疗提升 10-15%，术后恢复时间缩短约 30%。 在市场竞争层面，CybeRay 相较瑞典医科达 Leksell Gamma Knife，不仅在价格上更具优势（约低 30-40%）， 也凭借头体两用和实 ...

协办单位：启迪之星， 禾芫科技孵化器， 中关村科学城CGT产业孵化中心 五、大会议程 | 时间 主题和喜宾 | | | --- | --- | | 9:00-9:06 致辞环节 | | | 林航,海淀区 副区长(拟) | | | 刘慧,北京医药健康科技发展中心 主任(拟) | | | 王广志,清华大学 生物医学工程学院 执行 | | | 院长 (拟) | | | 9:06-9:15 | 全球科技创新系列奖项颁布 | | 9:15-9:35 | 医疗器械 BD: 现状与未来趋势 | | 9:35-9:55 | 《构建医院创新生态助力医工结合创新发 | | 展》 | | | 王昊 天坛医院科技处处长 | | | 9:55-10:15 | 题目待定 | | 逢宇 北京胸科医院 细菌免疫室主任和科研 | | | 处处长,结核病防治关键技术北京重点实验 | | | 室主任 | | | 10:15-10:35 《人工智能医疗器械产业发展探讨》 | | | 赵阳光,中国信息通信研究院云大所生物科 | | | 技部副主任 | | | 10:35-10:55 《可穿戴脑机接口与精神疾病诊疗》 | | | 左年明,中科院自动化所 ...

最新一期业绩显示，2025年一季报，公司实现营业收入82.37亿元，同比-12.12%；净利润26.29亿元，同 比-16.81%，销售毛利率62.53%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13迈瑞医疗23.3522.296.742600.44亿行业平均 51.3648.894.49106.66亿行业中值37.2238.152.4951.36亿1九安医疗10.2510.370.81173.02亿2英科医疗 10.9511.800.97172.95亿3新华医疗14.3013.251.1791.67亿4奥美医疗15.3515.051.5855.47亿5振德医疗 15.3814.490.9855.82亿6山东药玻15.5415.591.79146.99亿7康德莱15.8115.821.3134.07亿8奥泰生物 16.4317.331.3352.40亿9维力医疗16.5717.221.9437.78亿10九强生物16.5815.422.0382.13亿11安杰思 17.3817.592.1051.60亿12三鑫医疗18.8118.813.0942.78亿 来源：金融界 资金流向方面，7月9日， ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Tongjing Life, which closed at 15.24 yuan with a PE ratio of 62.73, marking a new low in 75 days, and a total market capitalization of 2.477 billion yuan [1] - The average PE ratio for the medical device industry is 51.36, with a median of 37.22, placing Tongjing Life at the 92nd position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Tongjing Life is 17,040, a decrease of 590 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Tongjing Life focuses on the research, production, and sales of in vitro diagnostic products under its own brand, with major products including diagnostic reagents, instruments, and service income [1] - The company actively participates in various health-themed public welfare activities and has received multiple awards for its social responsibility efforts, including the "Social Public Welfare Award" from the China Cancer Foundation [1] - In the latest quarterly report for Q1 2025, Tongjing Life reported an operating revenue of 74.8931 million yuan, a year-on-year decrease of 19.53%, and a net profit of 471,700 yuan, a year-on-year increase of 110.51%, with a gross profit margin of 63.66% [1]

Company Overview - LeXin Medical focuses on health IoT and digital health services, offering products such as smart electronic blood pressure monitors, health scales, blood glucose monitoring devices, fat measuring instruments, ECG monitoring equipment, smart bands, and smartwatches [2] - The company is recognized as a national high-tech enterprise and has established several research and development centers, including the Guangdong Provincial Engineering Technology Research Center [2] - LeXin Medical has obtained various international certifications, including ISO13485:2016, ISO9001:2015, ISO14001:2015, FDA registration, CE certification, and others, indicating its commitment to quality and international standards [2] Financial Performance - In the first quarter of 2025, LeXin Medical reported revenue of 273 million yuan, representing a year-on-year increase of 9.90%, and a net profit of 22.94 million yuan, up 67.88% year-on-year, with a gross profit margin of 37.38% [2] - As of July 9, 2023, the company's stock closed at 15.85 yuan, with a rolling PE ratio of 48.79, marking a new low in 65 days, and a total market capitalization of 3.447 billion yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 51.36, with a median of 37.22, placing LeXin Medical at the 87th position within the industry [1][3] - The company's current PE ratio is lower than the industry average, indicating potential valuation opportunities [1][3]

Company Overview - The main business of the company is the research, production, sales, and related services of in vitro diagnostic products, including a wide range of test reagents for liver function, kidney function, glucose metabolism, lipid metabolism, infectious diseases, and more [2]. Financial Performance - In the first quarter of 2025, the company reported revenue of 510 million yuan, a year-on-year decrease of 17.22%, and a net profit of 23.98 million yuan, down 80.09% year-on-year, with a gross profit margin of 56.76% [2]. Market Position - As of July 9, the company's stock closed at 12.24 yuan, up 1.92%, with a rolling price-to-earnings (PE) ratio of 247.07, marking a new low in 65 days. The total market capitalization is 7.497 billion yuan [1]. - The average PE ratio in the medical device industry is 51.36, with a median of 37.22, placing the company at the 119th position in the industry ranking [1][3]. Shareholder Information - As of March 31, 2025, the number of shareholders is 35,022, a decrease of 1,242 from the previous count, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1].

股东方面，截至2025年6月30日，冠昊生物股东户数32645户，较上次减少515户，户均持股市值35.28万 元，户均持股数量2.76万股。 冠昊生物科技股份有限公司的主营业务是致力于开发具有自主知识产权的新产品、新技术,将提升产品 质量、优化产品结构视为企业发展的核心驱动力,积极应对市场挑战,不断调整优化营销策略,积极提升品 牌影响力和市场占有率,不断推动公司核心业务生物材料、药业、细胞三大业务板块的协同快速发展。 公司的主要产品是生物型硬脑（脊）膜补片、B型硬脑（脊）膜补片、胸普外科修补膜、无菌生物护创 膜、艾瑞欧乳房补片、优得清脱细胞角膜植片。公司作为"国家知识产权优势企业"，其中商标"冠昊生 物""欣比克"纳入广东省重点商标保护名录。冠昊生物及下属子公司北昊研究院、中昊药业、武汉北度 均为高新技术企业；冠昊生物、北昊研究院、中昊药业均为广东省专精特新中小企业；冠昊科技园为国 家级科技企业孵化器、广州市中小企业服务站、优秀科技金融工作站、青年众创空间、粤港澳青少年交 流活动基地、黄埔区企业家服务中心工作站。 最新一期业绩显示，2025年一季报，公司实现营业收入9479.71万元，同比3.67%；净利润 ...

截至2025年一季报，共有23家机构持仓三诺生物，其中基金21家、其他2家，合计持股数9724.15万股， 持股市值23.13亿元。 三诺生物传感股份有限公司的主营业务是血糖监测系统的生产和销售。公司的主要产品是血糖监测系 统、糖尿病营养、护理等辅助产品、血脂检测系统、iPOCT监测系统、糖化血红蛋白检测系统、血压 计、经营品。公司作为血糖监测领域领先企业，先后荣获"国家企业技术中心"、"国家工程研究中 心"、"国家技术创新示范企业"、"国家知识产权优势企业"、"国家科技进步二等奖"和"国家绿色工厂"等 资质。 最新一期业绩显示，2025年一季报，公司实现营业收入10.42亿元，同比2.76%；净利润7211.51万元， 同比-10.90%，销售毛利率48.69%。 7月9日，三诺生物今日收盘22.25元，上涨1.14%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到39.55倍，总市值125.55亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.36倍，行业中值37.22倍，三诺生物排 名第81位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13三诺生物39.55 ...

Group 1 - The stock of Rejing Bio (688068) has a strong overall score of 63.80 as of July 9, 2025, indicating a positive outlook [1][2] - The main cost analysis shows the current main cost at 184.00 yuan, with a 5-day average of 179.53 yuan, a 20-day average of 152.13 yuan, and a 60-day average of 133.13 yuan [1][2] - The stock has experienced 3 instances of hitting the upper limit and no instances of hitting the lower limit in the past year [1] Group 2 - The short-term resistance level is at 194.81 yuan, while the short-term support level is at 147.07 yuan [2] - The market trend is currently unclear, with a wait-and-see approach for the main funds to choose a direction [2] - The K-line pattern indicates a bullish outlook with a "solid bullish line" [2] Group 3 - On July 9, 2025, the net inflow of main funds was 64.97 million yuan, accounting for 9% of the total transaction volume [2][3] - The breakdown of fund inflows includes a net inflow of 50.48 million yuan from large orders and 14.49 million yuan from medium orders, while retail investors saw a net outflow of 2.33 million yuan [2][3] - The financial data shows an earnings per share of -0.26 yuan, an operating profit of -0.24 billion yuan, and a net profit of -24,566,770.04 yuan, with a sales gross margin of 47.268% [2][3] Group 4 - The stock is associated with sectors such as medical devices (0.01%), food safety (-0.09%), national security (-0.28%), and in vitro diagnostics (-0.16%) [2][3]

三、安徽省阜阳市颍东区市场监管局查处安徽全康药业有限公司违法广告案 经查，安徽全康药业有限公司在互联网推广"永邦牌葛根豆蔻片"等保健食品过程中，通过宣称"日产80 万瓶""20余年实力大厂"等与实际情况不符的信息，对消费者造成误导。 今年6月，安徽省阜阳市颍东区市场监管局依据《中华人民共和国广告法》有关规定，对安徽全康药业 有限公司作出罚款21万元的行政处罚。 今年以来，全国市场监管部门持续加大对违法广告的打击力度，防范经营主体借违法广告加剧"内卷 式"竞争，切实维护公平有序的广告市场秩序。截至2025年5月底，全国市场监管部门共查处违法广告案 件14315件，罚没款1.01亿元。现选取一批已办结的违法广告典型案例予以公布。 一、四川省成都市成华区市场监管局查处成都成华韩后医疗美容医院有限公司违法广告案 经查，成都成华韩后医疗美容医院有限公司在以直播电商形式推销"半岛超声炮""欧洲之星全面部全模 式""星耀超光子"等医疗美容项目过程中，宣称的治疗功效与实际情况不符，并使用"单次我们的续航能 力是9—12个月""能够解决肌肤20多种问题"等宣传用语为功效作保证。 今年1月，四川省成都市成华区市场监管局依据《中华 ...